Victory Capital Management Inc. Raises Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Victory Capital Management Inc. lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 21.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 186,819 shares of the biotechnology company’s stock after purchasing an additional 33,599 shares during the period. Victory Capital Management Inc. owned 0.42% of United Therapeutics worth $66,947,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sei Investments Co. lifted its holdings in shares of United Therapeutics by 3.2% in the 1st quarter. Sei Investments Co. now owns 37,257 shares of the biotechnology company’s stock worth $8,562,000 after buying an additional 1,149 shares during the period. ProShare Advisors LLC lifted its stake in United Therapeutics by 2.1% in the first quarter. ProShare Advisors LLC now owns 5,589 shares of the biotechnology company’s stock worth $1,284,000 after acquiring an additional 117 shares during the period. State Board of Administration of Florida Retirement System grew its holdings in United Therapeutics by 2.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 48,197 shares of the biotechnology company’s stock worth $10,794,000 after acquiring an additional 1,200 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares in the last quarter. Finally, Intech Investment Management LLC increased its position in United Therapeutics by 1,973.9% during the 1st quarter. Intech Investment Management LLC now owns 19,412 shares of the biotechnology company’s stock valued at $4,459,000 after purchasing an additional 18,476 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Bank of America lowered their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $370.86.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the sale, the director now directly owns 5,655 shares of the company’s stock, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total value of $1,239,048.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $44,743.40. This represents a 96.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 113,396 shares of company stock worth $42,175,418 over the last quarter. Insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 3.5 %

NASDAQ:UTHR opened at $386.27 on Friday. The firm has a fifty day simple moving average of $362.57 and a 200-day simple moving average of $326.65. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The company has a market capitalization of $17.25 billion, a P/E ratio of 16.96, a PEG ratio of 1.17 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the previous year, the business earned $5.38 EPS. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Co. will post 25.1 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.